RSB Spine, LLC, Announces FDA Clearance for Its InterPlate(TM) C-PS and L-PS Interbody Spacers

CLEVELAND, Jan. 28 /PRNewswire/ -- RSB Spine, LLC, today announced that the U.S. Food and Drug Administration has approved the company's 510(k) application to permit the marketing of its InterPlate™ C-PS and L-PS Interbody Spacers.

RSB Spine Chief Executive Officer John A. Redmond said: "We are very excited about this new clearance, since it gives our distributors two additional products to offer customers seeking greater options in Zero-Profile® technologies. Our InterPlate portfolio now provides surgeons with the most unique implant combinations on the market."

"Zero-Profile technologies comprise one of the fastest growing segments in the spinal industry," said Mike O'Neill, president of Paradigm BioDevices. "RSB Spine is the only company with a full-line modular interbody platform offering a complete array of material and mechanical loading options that is also code compliant."

RSB Spine is a privately held medical device company focused on developing innovative spinal implants with a focus on modular fusion products. News releases and other information on the company are available on the Internet at: http://www.rsbspine.com.

Zero-Profile® is a registered Service Mark of Paradigm BioDevices, Inc., Rockland, MA.

SOURCE RSB Spine, LLC